You have 9 free searches left this month | for more free features.

Carboplatin

Showing 1 - 25 of 3,600

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Head and Neck Squamous Cell Carcinoma Trial in United States (TAK-676, Carboplatin, 5-FU)

Completed
  • Head and Neck Squamous Cell Carcinoma
  • Shreveport, Louisiana
  • +3 more
Oct 3, 2023

Recurrent Ovarian Cancer, Recurrent Uterine Cancer, Metastatic Cancer Trial in Toronto (RP-6306, Carboplatin, Paclitaxel)

Not yet recruiting
  • Recurrent Ovarian Cancer
  • +3 more
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
Oct 25, 2023

Prostate Cancer Trial in Houston (ADI-PEG 20, Cabazitaxel, Carboplatin)

Not yet recruiting
  • Prostate Cancer
  • ADI-PEG 20
  • +2 more
  • Houston, Texas
    MD Anderson Cancer Center
Oct 16, 2023

Advanced Epithelial Ovarian Cancer Trial in Cairo (Carboplatin/paclitaxel)

Completed
  • Advanced Epithelial Ovarian Cancer
  • Cairo, Egypt
    Pharmacology and toxicology department, Faculty of Pharmacy, Cai
Jul 19, 2023

Recurrent Ovarian Cancer Trial in Pittsburgh (CPI-0209, carboplatin)

Not yet recruiting
  • Recurrent Ovarian Cancer
  • Pittsburgh, Pennsylvania
    Magee-Womens Research Institute / UPMC Magee Womens Hospital
Jul 3, 2023

Merkel Cell Carcinoma Trial in Milano, Siena, Verona (Pembrolizumab, Etoposide, Cisplatin or Carboplatin)

Not yet recruiting
  • Merkel Cell Carcinoma
  • Pembrolizumab, Etoposide, Cisplatin or Carboplatin
  • Milano, Italy
  • +2 more
Oct 10, 2023

Ovarian Cancer Trial (Aribulin;carboplatin;bevacizumab)

Not yet recruiting
  • Ovarian Cancer
  • (no location specified)
Jul 20, 2023

Locally Advanced Breast Cancer, Chemo Effect Trial in Beijing (inetetamab with pertuzumab and paclitaxel/carboplatin (TCbIP)

Recruiting
  • Locally Advanced Breast Cancer
  • Chemotherapy Effect
  • inetetamab with pertuzumab and paclitaxel/carboplatin (TCbIP) regimen
  • Beijing, China
    National Cancer Center/National Clinical Research Center for Can
Feb 28, 2023

Breast Cancer, Neoadjuvant Trial in Wuhan (pyrotinib,Trastuzumab,carboplatin,Albumin paclitaxel)

Recruiting
  • Breast Cancer
  • Neoadjuvant
  • pyrotinib,Trastuzumab,carboplatin,Albumin paclitaxel
  • Wuhan, Hubei, China
  • +1 more
Aug 18, 2023

HNSCC, Oral Cancer, PD-1 Trial in Guangzhou (Perbolizumab+Carboplatin+albumin-bound paclitaxel:4 courses,

Recruiting
  • HNSCC
  • +2 more
  • Perbolizumab+Carboplatin+albumin-bound paclitaxel:4 courses
  • Perbolizumab+Carboplatin+albumin-bound paclitaxel:2 courses
  • Guangzhou, Guangdong, China
    Sun yat-sen memorial hospital
Aug 6, 2023

HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients Trial (PERT-IJS plus trastuzumab,

Not yet recruiting
  • HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients
  • PERT-IJS plus trastuzumab, carboplatin and docetaxel
  • Perjeta plus trastuzumab, carboplatin and docetaxel
  • (no location specified)
Sep 21, 2023

Urinary Bladder Cancer Trial in Assiut (Carboplatin-Gemcitabine Cisplatin-Gemcitabine)

Recruiting
  • Urinary Bladder Cancer
  • Carboplatin-Gemcitabine Cisplatin-Gemcitabine
  • Assiut, Egypt
    AssiutU
Apr 22, 2023

Advanced Solid Tumors Trial in Netherlands, Spain (Debio 0123, Carboplatin)

Recruiting
  • Advanced Solid Tumors
  • Debio 0123
  • Carboplatin
  • Groningen, Netherlands
  • +3 more
Jan 27, 2023

Metastatic Triple-Negative Breast Cancer Trial in Charlotte (Trilaciclib, Pembrolizumab, Gemcitabine)

Not yet recruiting
  • Metastatic Triple-Negative Breast Cancer
  • Charlotte, North Carolina
    Levine Cancer Institute
Aug 31, 2023

Ovarian Cancer Trial in San Diego (VS-6063, Paclitaxel, Carboplatin)

Recruiting
  • Ovarian Cancer
  • San Diego, California
    University of California San Diego
Feb 1, 2023

Head and Neck Squamous Cell Carcinoma, Oral Cancer Trial in Guangzhou (Tirelizumab ,+Carboplatin+albumin-bound paclitaxel)

Recruiting
  • Head and Neck Squamous Cell Carcinoma
  • Oral Cancer
  • Tirelizumab ,+Carboplatin+albumin-bound paclitaxel
  • Guangzhou, Guangdong, China
    Sun yat-sun memorial hospital
Jul 10, 2023

Metastatic Breast Cancer, Triple Negative Breast Cancer, Estrogen-receptor-low Breast Cancer Trial in Carmel, Indianapolis

Not yet recruiting
  • Metastatic Breast Cancer
  • +2 more
  • Carmel, Indiana
  • +2 more
Apr 27, 2023

NSCLC Metastatic Trial (Atezolizumab, Nab paclitaxel, Carboplatin)

Not yet recruiting
  • Non-Small Cell Lung Cancer Metastatic
  • (no location specified)
Jan 18, 2023

Adult Solid Tumor Trial in Chicago (Carboplatin, Laboratory Biomarker Analysis, Paclitaxel)

Active, not recruiting
  • Adult Solid Neoplasm
  • Carboplatin
  • +4 more
  • Chicago, Illinois
    University of Chicago Comprehensive Cancer Center
Jan 25, 2023

Triple Negative Metastatic Breast Cancer, Advanced Ovarian Cancer, Carboplatin Trial in Belgium, Netherlands, United Kingdom

Active, not recruiting
  • Triple Negative Metastatic Breast Cancer
  • +3 more
  • KU-0059436 (AZD2281)(PARP inhibitor)
  • +3 more
  • Brussels, Belgium
  • +3 more
Dec 19, 2022

Lung Cancer Trial in Tampa, Columbus (Carboplatin, Paclitaxel, AZD1775)

Active, not recruiting
  • Lung Cancer
  • Carboplatin
  • +2 more
  • Tampa, Florida
  • +1 more
Feb 2, 2023

Triple-negative Breast Cancer Trial (Taxane and Carboplatin, Short-term Sintilimab, Surgery)

Not yet recruiting
  • Triple-negative Breast Cancer
  • Taxane and Carboplatin
  • +2 more
  • (no location specified)
Apr 25, 2023

NSCLC Trial in Seoul (Lazertinib/Pemetrexed/Carboplatin)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • Seoul, Korea, Republic of
    Yonsei University Health System, Severance Hospital
Mar 23, 2023

Castration-resistant Prostate Cancer, Homologous Recombination Deficiency Trial in Sydney (Testosterone Enanthate 100 MG/ML

Recruiting
  • Castration-resistant Prostate Cancer
  • Homologous Recombination Deficiency
  • Testosterone Enanthate 100 MG/ML Injectable Solution
  • Testosterone Enanthate 100 MG/ML Injectable Solution / Carboplatin AUC 5
  • Sydney, New South Wales, Australia
    Kinghorn Cancer Centre, St. Vincent's Hospital
Dec 16, 2022